Condition

Relapsed/Refractory Plasma Cell Leukemia clinical trials and research

• 2Clinical trials
• 1Country

All recruiting trials (2)

• CT0596 CAR-T treatment for relapsed or refractory multiple myeloma and plasma cell leukemia

  This will try a CT0596 CAR‑T cell infusion in adults whose multiple myeloma or plasma cell leukemia has returned or not responded to prior treatments to see if it is safe and can control the disease.

  Recruiting Early Phase 1 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT06730256

• CT0596 treatment for patients with relapsed or refractory multiple myeloma and plasma cell leukemia

  This study is testing a new CAR-T cell therapy called CT0596 to see if it can help people with relapsed or hard-to-treat multiple myeloma and plasma cell leukemia.

  Recruiting Early Phase 1 Shanghai Changzheng Hospital · Shanghai, Shanghai Municipality · NCT06718270

Related topics

Quick answers

How many Relapsed/Refractory Plasma Cell Leukemia clinical trials are recruiting right now?

2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in China. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Early Phase 1: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →